Modelling anti-pertussis toxin IgG antibody decay following primary and preschool vaccination with an acellular pertussis vaccine in UK subjects using a modified oral fluid assay
Recent vaccination with pertussis vaccine can confound serological and oral fluid (OF) assays targeting anti-pertussis toxin (anti-PT) IgG antibodies as a marker of recent infection. This study sought to establish the minimum potentially confounding time period based on experimental data to assist interpretation from such samples submitted from UK subjects for pertussis diagnosis. Anti-PT IgG antibody response and decay were measured post-vaccination using a modified OF IgG antibody-capture ELISA (GACELISA). Data were obtained from 72 infants after the third acellular pertussis vaccine dose in the primary schedule (4 months of age) and from 119 children after the single dose at preschool age (3 years 4 months to 5 years 8 months of age). Specimens were taken at approximately 1 month intervals for 9 months post-primary immunization (third dose) and 13 months post-preschool booster (PSB). The modified GACELISA demonstrated a sensitivity of 52/56 (92.9 %: 95 % CI 82.7–98.0) and a specificity of 120/128 (93.8 %: 95 % CI 88.0–97.3) and showed good agreement with the National Reference Laboratory standard anti-PT IgG serum ELISA (rank correlation = 0.80) and the original OF assay (rank correlation = 0.79). Modelling of the decline in antibody titres showed a reduction of 54 % and 34 % for each doubling of time after day 14 for the post-third primary dose and post-PSB subjects, respectively. These data suggest that the minimum confounding time period is approximately 300 days for samples obtained post-primary immunization and at least 3 years for samples submitted from UK children following immunization with the PSB. These data will greatly assist the interpretation of single high diagnostic anti-PT IgG titres by allowing an estimate of the positive predictive value, when the number of days post-immunization and prevalence are known or assumed.
BorrowR., AndrewsN., FindlowH., WaightP., SouthernJ., Crowley-LukeA., StapleyL., EnglandA., FindlowJ., MillerE.2010; Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine. Clin Vaccine Immunol 17:154–159 [View Article][PubMed]
CampbellH., AmirthalingamG., AndrewsN., FryN. K., GeorgeR. C., HarrisonT. G., MillerE.2012; Accelerating control of pertussis in England and Wales. Emerg Infect Dis 18:38–47 [View Article][PubMed]
DalbyT., PetersenJ. W., HarboeZ. B., KrogfeltK. A.2010; Antibody responses to pertussis toxin display different kinetics after clinical Bordetella pertussis infection than after vaccination with an acellular pertussis vaccine. J Med Microbiol 59:1029–1036 [View Article][PubMed]
FryN. K., DuncanJ., WagnerK., TzivraO., DoshiN., LittD. J., CrowcroftN., MillerE., GeorgeR. C., HarrisonT. G.2009; Role of PCR in the diagnosis of pertussis infection in infants: 5 years’ experience of provision of a same-day real-time PCR service in England and Wales from 2002 to 2007. J Med Microbiol 58:1023–1029 [View Article][PubMed]
GuisoN., BerbersG., FryN. K., HeQ., RiffelmannM., Wirsing von KönigC. H.EU Pertstrain group2011; What to do and what not to do in serological diagnosis of pertussis: recommendations from EU reference laboratories. Eur J Clin Microbiol Infect Dis 30:307–312 [View Article][PubMed]
HarndenA., GrantC., HarrisonT., PereraR., BrueggemannA. B., Mayon-WhiteR., MantD.2006; Whooping cough in school age children with persistent cough: prospective cohort study in primary care. BMJ 333:174–177 [View Article][PubMed]
HeQ., BarkoffA. M., MertsolaJ., GlismannS., BacciS.European Bordetella expert group (EUpertstrain)European surveillance network for vaccine-preventable diseases (EUVAC.NET)2012; High heterogeneity in methods used for the laboratory confirmation of pertussis diagnosis among European countries, 2010: integration of epidemiological and laboratory surveillance must include standardisation of methodologies and quality assurance. Euro Surveill 17:20239[PubMed]
LearyJ. J., BrigatiD. J., WardD. C.1983; Rapid and sensitive colorimetric method for visualizing biotin-labeled DNA probes hybridized to DNA or RNA immobilized on nitrocellulose: Bio-blots. Proc Natl Acad Sci U S A 80:4045–4049 [View Article][PubMed]
LittD. J., SamuelD., DuncanJ., HarndenA., GeorgeR. C., HarrisonT. G.2006; Detection of anti-pertussis toxin IgG in oral fluids for use in diagnosis and surveillance of Bordetella pertussis infection in children and young adults. J Med Microbiol 55:1223–1228 [View Article][PubMed]
MorrisM., CohenB., AndrewsN., BrownD.2002; Stability of total and rubella-specific IgG in oral fluid samples: the effect of time and temperature. J Immunol Methods 266:111–116 [View Article][PubMed]
SheppardC., CohenB., AndrewsN., SurridgeH.2001; Development and evaluation of an antibody capture ELISA for detection of IgG to Epstein-Barr virus in oral fluid samples. J Virol Methods 93:157–166 [View Article][PubMed]
TowbinH., StaehelinT., GordonJ.1979; Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 76:4350–4354 [View Article][PubMed]
WilsonM. B., NakaneP. K.1978; Recent developments in the periodate method of conjugating horseradish peroxidase (HRPO) to antibodies. In Immunofluorescence and Related Staining Techniques pp. 215–224 Edited by KnappW., WickG., HolubarK. Amsterdam: Elsevier;
Modelling anti-pertussis toxin IgG antibody decay following primary and preschool vaccination with an acellular pertussis vaccine in UK subjects using a modified oral fluid assay